Comprehensive study on central precocious puberty: molecular and clinical analyses in 90 patients.

MECP2 MKRN3 Central precocious puberty Imprinted genes Imprinting disorders Temple syndrome

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
26 Sep 2024
Historique:
received: 06 06 2024
revised: 25 08 2024
accepted: 24 09 2024
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 26 9 2024
Statut: aheadofprint

Résumé

Defects in MKRN3, DLK1, KISS1, and KISS1R and some disorders, such as Temple syndrome (TS14), cause central precocious puberty (CPP). Recently, pathogenic variants (PVs) in MECP2 have been reported to be associated with CPP. We aimed to clarify the contribution of (epi)genetic abnormalities to CPP and clinical and hormonal features in each etiology. We conducted targeted sequencing for MKRN3, DLK1, MECP2, KISS1, and KISS1R and methylation analysis for screening of imprinting disorders such as TS14 associated with CPP in 90 patients with CPP (no history of brain injuries and negative brain MRI) and collected their clinical and laboratory data. We measured serum DLK1 levels in three patients with TS14 and serum MKRN3 levels in two patients with MKRN3 genetic defects, together with some etiology-unknown patients with CPP and controls. We detected eight patients with TS14 (six, epimutation; one, mosaic maternal uniparental disomy chromosome 14; one, microdeletion) and three patients with MKRN3 genetic defects (one, PV; one, 13-bp deletion in the 5'-untranslated region (5'-UTR); one, microdeletion) with family histories of paternal early puberty. There were no patients with PVs identified in MECP2, KISS1, or KISS1R. We confirmed low serum MKRN3 level in the patient with a deletion in 5'-UTR. The median height at initial evaluation of TS14 patients was lower than that of all patients. Six patients with TS14 were born small for gestational age (SGA). (Epi)genetic causes were identified in 12.2% of patients with CPP at our center. For patients with CPP born SGA or together with family histories of paternal early puberty, (epi)genetic testing for TS14 and MKRN3 genetic defects should be considered. (271/250).

Identifiants

pubmed: 39324648
pii: 7776052
doi: 10.1210/clinem/dgae666
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.

Auteurs

Hiromune Narusawa (H)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.
Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Chuo, Japan.

Tomoe Ogawa (T)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.

Hideaki Yagasaki (H)

Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Chuo, Japan.

Keisuke Nagasaki (K)

Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan.

Tatsuki Urakawa (T)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.

Tomohiro Saito (T)

Department of Pediatrics, Yamanashi Prefectural Central Hospital, Kofu, Japan.

Shun Soneda (S)

Tanaka Growth Clinic, Tokyo, Japan.
Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan.

Saori Kinjo (S)

Department of Pediatrics, Okinawa Chubu Hospital, Uruma, Japan.

Shinichiro Sano (S)

Department of Pediatric Endocrinology and Metabolism, Shizuoka Children's Hospital, Shizuoka, Japan.

Mitsukazu Mamada (M)

Department of Pediatrics, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Shintaro Terashita (S)

Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan.

Sumito Dateki (S)

Department of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Satoshi Narumi (S)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.

Yasuhiro Naiki (Y)

Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan.

Reiko Horikawa (R)

Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan.

Tsutomu Ogata (T)

Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Department of Pediatrics, Hamamatsu Medical Center, Hamamatsu, Japan.

Maki Fukami (M)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.

Masayo Kagami (M)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.

Classifications MeSH